People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Other Technology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sequelae, Inc. | — | Other Technology | Series C | $80.2M | $1.4M | 2023 |
| ExceleraRx Corp. | — | Other Health Care | Seed | $4.9M | $49.6M | 2019 |
Albert Zimmerli at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Albert Zimmerli on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amy Schulman | 1 | 11 |
| Gregory Johnson | 1 | 8 |
| Scott Peterson | 1 | 4 |
| RUSHIKA FERNANDOPULLE | 1 | 2 |
| Ken Ehlert | 1 | 2 |
| Dave Fasching | 1 | 1 |
| David W. Christensen | 1 | 1 |
| John S. Polanski | 1 | 1 |
| Robert W. Beacher | 1 | 1 |
| Sara Taylor | 1 | 1 |
| Mike Christy | 1 | 1 |
| David Wichmann | 1 | 1 |
| Mark Briesacher | 1 | 1 |
| David Wichman | 1 | 1 |
| Shiraz Fagan | 1 | 1 |
| Mark Pollman | 1 | 1 |
| Mark Pollmann | 1 | 1 |
| George Chresand | 1 | 1 |
| Sandra Mayasich | 1 | 1 |
| Daniel Kus | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.